INmune Bio Inc. (INMB) financial statements (2021 and earlier)

Company profile

Business Address 1200 PROSPECT STREET
LA JOLLA, CA 92037
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,9967,3839,3646,049 
Cash and cash equivalents6,9967,3839,3646,049 
Receivables77106105166 
Prepaid expense98122200276 
Other undisclosed current assets5941,0731,138640 
Total current assets:7,7658,68310,8077,131 
Noncurrent Assets
Operating lease, right-of-use asset192199  
Intangible assets, net (including goodwill)16,51416,51416,51416,514 
Intangible assets, net (excluding goodwill)16,51416,51416,51416,514 
Other undisclosed noncurrent assets  209  
Total noncurrent assets:16,70616,71316,72316,514 
TOTAL ASSETS:24,47025,39627,53023,645 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:402337438472 
Other undisclosed accounts payable and accrued liabilities402337438472 
Debt816   
Due to related parties290162709 
Other undisclosed current liabilities  8  
Total current liabilities:700516516481 
Noncurrent Liabilities
Long-term debt and lease obligation160172   
Operating lease, liability160172  
Other undisclosed noncurrent liabilities  177  
Total noncurrent liabilities:160172177  
Other undisclosed liabilities   300 
Total liabilities:861687693781 
Stockholders' equity
Stockholders' equity attributable to parent, including:23,61024,70926,83722,864 
Common stock11111110 
Additional paid in capital44,83443,66142,68733,671 
Accumulated other comprehensive income (loss)(9)(55)(19)6 
Accumulated deficit(21,276)(18,958)(15,891)(15,499) 
Other undisclosed stockholders' equity attributable to parent5050504,676 
Total stockholders' equity:23,61024,70926,83722,864 
TOTAL LIABILITIES AND EQUITY:24,47025,39627,53023,645 

Income statement (P&L) ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
Operating expenses(2,332)(3,084)(428)(1,911) 
Operating loss:(2,332)(3,084)(428)(1,911) 
Nonoperating income
(Other Nonoperating income)
14173610 
Net loss available to common stockholders, diluted:(2,318)(3,067)(392)(1,901) 

Comprehensive Income ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
Net loss:(2,318)(3,067)(392)(1,901) 
Comprehensive loss:(2,318)(3,067)(392)(1,901) 
Other undisclosed comprehensive income (loss), net of tax, attributable to parent46(36)(25)(1) 
Comprehensive loss, net of tax, attributable to parent:(2,272)(3,103)(417)(1,902) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: